Avantis国际大型价值股主动型ETF AVIV 深 沪
已收盘 08-14 16:00:00 美东时间
83.15
+0.350
+0.42%
华盛通- 最 高83.31
- 今 开83.07
- 成交量 4.76万股
- 最 低 83.034
- 昨 收 82.80
- 总市值 207.04万
- 52周最高 83.31
- 市盈率 静 --
- 换手率 191.27%
- 52周最低 62.9331
- 委 比 0.00%
- 总股本 2.49万
- 历史最高 83.31
- 量 比 0.43
- 振 幅 0.33%
- 历史最低 30.2933
- 每 手 1
- 风险率 5.79%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多RedHill Biopharma Engages WHO Solidarity Platform And Pharma Partners To Advance Opaganib As Oral Host Directed Therapy For Ebola Virus Disease Amid Bundibugyo Outbreak Showing Preclinical Filovirus Activity And Prior Phase 3 Antiviral Results
Amid the rapidly evolving Ebola virus disease (EVD) outbreak involving the rare Bundibugyo ebolavirus sub-type, for which there are no approved medications or vaccines, RedHill Biopharma is actively discussing
06-04 00:10
Teva Pharmaceutical Industries Subsidiary And Medincell Says European Medicines Agency Has Accepted The Marketing Authorization Application For Olanzapine Long-Acting Injectable (TEV-'749) For The Treatment Of Schizophrenia In Adults
The olanzapine long-acting injectable (TEV-'749) is designed to deliver the efficacy of olanzapine in a subcutaneous formulation1 administered every four weeks.If approved, TEV-‘749 could help fill a significant unmet
05-22 00:33
Innoviz Technologies Announces Software Development Agreement With Autonomous Driving Technology Company To Evaluate On-Sensor LiDAR Perception Capabilities For InnovizTwo LiDAR Platform And Deliver Development Plan
Innoviz enters into a new agreement with a leading autonomous driving technology company to evaluate the development of enhanced on-sensor perception softwareTEL AVIV, Israel, May 13, 2026 /PRNewswire/ -- Innoviz
05-13 20:09
Redhill Biopharma Announces New In Vitro Testing Results Demonstrating RHB-204's Comparability To RHB-104 In Mycobacterium Avium Subspecies Paratuberculosis Killing Efficacy
RHB-2041 is a next-generation optimized formulation of RedHill's oral RHB-1042, designed for enhanced tolerability, safety profile and patient adherence, that employs a groundbreaking Mycobacterium avium subspecies
04-30 19:12
